The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .

Inclusion Criteria:

1. Male or female patients .
2. Confirmed by Histopathology or Cytology of Lung Cancer
3. Patients should be voluntary to the trial and provide with signed informed consent
4. The researchers believe patients can benefit from the study.

Exclusion Criteria:

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories
2. Pregnant or lactating women
3. Patients with Albumin-binding taxol contraindications
4. Patients of doctors considered unsuitable for the trial

Confirmed by Histopathology or Cytology of Lung cancer

Within six months after the trial complete.

The data will be disclosed within six months after completion of the study.